ENG and renal cell adenocarcinoma: (117) experimentally tested the effects of TRC 105 (antibodies against CD105) combined with or without Sunitib on the cc-RCC-derived tumor endothelial cells (TEC) and CD105+ cancer stem cell-derived endothelial progenitor cells (CSC-TEC).